Quest Diagnostics and CDC expand hepatitis research collaboration

Quest Diagnostics has been awarded a contract by the U.S. Centers for Disease Control and Prevention – CDC – designed to assess the burden of hepatitis C virus – HCV – in the U.S. Quest will perform both HCV antibody testing and molecular RNA testing using HIPAA-deidentified “remnant” specimens randomly selected from clinical test specimens. The goal is to gain a better understanding of the burden of hepatitis C infection in the United States.